Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

BGNE

BeiGene (BGNE)

BeiGene Ltd

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:BGNE

<< Previous 1 2 3 4 5 6 7 8 9 10 11 12 Next >>

Date	Time	Source	Headline	Symbol	Company
02/26/2024	5:00AM	Business Wire	BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer	NASDAQ:BGNE	BeiGene Ltd
02/07/2024	6:47AM	PR Newswire (Canada)	Health Canada Approves BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma	NASDAQ:BGNE	BeiGene Ltd
02/07/2024	6:47AM	PR Newswire (Canada)	Santé Canada approuve BRUKINSA® (zanubrutinib) dans le traitement du lymphome folliculaire récidivant ou réfractaire	NASDAQ:BGNE	BeiGene Ltd
01/31/2024	6:47AM	PR Newswire (Canada)	Les adultes atteints de leucémie lymphoïde chronique (LLC) de l'Ontario et du Québec ont désormais accès à BRUKINSA® (zanubrutinib) grâce à un remboursement par le régime public	NASDAQ:BGNE	BeiGene Ltd
01/31/2024	6:47AM	PR Newswire (Canada)	Adults living with chronic lymphocytic leukemia (CLL) in Ontario and Quebec now have access, through public reimbursement, to BRUKINSA® (zanubrutinib)	NASDAQ:BGNE	BeiGene Ltd
01/24/2024	2:03PM	Business Wire	ベイジーン、取締役会に経験豊富なライフサイエンス界のエグゼクティブ、オリビエ・ブランディクールを迎える	NASDAQ:BGNE	BeiGene Ltd
01/23/2024	12:04PM	Business Wire	BeiGene accueille au sein de son conseil d'administration, Olivier Brandicourt, dirigeant expérimenté dans le domaine des sciences du vivant	NASDAQ:BGNE	BeiGene Ltd
01/23/2024	11:55AM	Business Wire	BeiGene heißt den erfahrenen Life Sciences Manager Olivier Brandicourt im Board of Directors willkommen	NASDAQ:BGNE	BeiGene Ltd
01/23/2024	6:03AM	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BGNE	BeiGene Ltd
01/23/2024	6:00AM	Business Wire	BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors	NASDAQ:BGNE	BeiGene Ltd
12/22/2023	6:00AM	Business Wire	FDA Approves Label Update for BRUKINSA® (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL)	NASDAQ:BGNE	BeiGene Ltd
12/21/2023	6:01AM	Business Wire	BeiGene to Present at the 42nd Annual J.P. Morgan Healthcare Conference	NASDAQ:BGNE	BeiGene Ltd
11/29/2023	4:01PM	Business Wire	BeiGene to Host ASH Investor Meeting in Person and via Webcast on December 10, 2023	NASDAQ:BGNE	BeiGene Ltd
11/28/2023	6:00AM	Business Wire	BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023	NASDAQ:BGNE	BeiGene Ltd
11/21/2023	6:00AM	Business Wire	BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor	NASDAQ:BGNE	BeiGene Ltd
11/17/2023	6:00AM	Business Wire	BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma	NASDAQ:BGNE	BeiGene Ltd
11/09/2023	4:08PM	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BGNE	BeiGene Ltd
11/09/2023	4:01PM	Business Wire	BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates	NASDAQ:BGNE	BeiGene Ltd
11/08/2023	6:00AM	Business Wire	BeiGene to Present at the Jefferies London Healthcare Conference	NASDAQ:BGNE	BeiGene Ltd
10/20/2023	4:04PM	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BGNE	BeiGene Ltd
10/20/2023	6:00AM	Business Wire	BRUKINSA® Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemia	NASDAQ:BGNE	BeiGene Ltd
10/17/2023	4:01PM	Business Wire	BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC)	NASDAQ:BGNE	BeiGene Ltd
10/17/2023	4:01PM	Business Wire	BeiGene Announces Late-Breaking Data at ESMO Showing Tislelizumab plus Chemotherapy Significantly Improved Overall Survival at Final Analysis in First-Line Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	NASDAQ:BGNE	BeiGene Ltd
10/16/2023	6:00AM	Business Wire	BeiGene Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeline Assets	NASDAQ:BGNE	BeiGene Ltd
10/13/2023	12:46PM	Dow Jones News	BeiGene Brukinsa Recommended for Approval From European Medicines Agency Committee	NASDAQ:BGNE	BeiGene Ltd
10/13/2023	11:51AM	Business Wire	BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma	NASDAQ:BGNE	BeiGene Ltd
09/19/2023	6:15AM	Business Wire	BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®	NASDAQ:BGNE	BeiGene Ltd
09/19/2023	6:00AM	Business Wire	BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)	NASDAQ:BGNE	BeiGene Ltd
08/31/2023	7:00AM	Business Wire	BeiGene to Present at the Morgan Stanley 21st Annual Global Healthcare Conference	NASDAQ:BGNE	BeiGene Ltd
08/29/2023	4:05PM	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BGNE	BeiGene Ltd

Showing the most relevant articles for your search:NASDAQ:BGNE

<< Previous 1 2 3 4 5 6 7 8 9 10 11 12 Next >>

Bell Buckle (PK)

ERHC Energy (CE)

RespireRx Pharmaceuticals (PK)

Anavex Life Sciences

Golden Triangle Ventures (PK)

Decentral Life (PK)

Branded Legacy (PK)

Valiant Eagle (PK)

Enzolytics (PK)

Delayed Upgrade Clock

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions